ReviewTrends in immunology2007
Antigen receptor signalling: a distinctive role for the p110delta isoform of PI3K.
Review in Trends in immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 121 citations in OpenAlex.
- First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases.European journal of clinical pharmacology · 2017Trial
- Gene expression profiling-based identification of CD28 and PI3K as new biomarkers for chronic graft-versus-host disease.DNA and cell biology · 2011Trial
- Trem2/Syk/PI3K axis contributes to the host protection against Toxoplasma gondii-induced adverse pregnancy outcomes via modulating decidual macrophages.PLoS pathogens · 2024Article
- Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives.Immunotherapy advances · 2024Review
- cis-B7:CD28 interactions at invaginated synaptic membranes provide CD28 co-stimulation and promote CD8Immunity · 2023Article
- The potential of FCRL genes as targets for cancer treatment: insights from bioinformatics and immunology.Aging · 2023Article
- Dual inhibition of phosphoinositide 3-kinases delta and gamma reduces chronic B cell activation and autoantibody production in a mouse model of lupus.Frontiers in immunology · 2023Article
- Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia.Molecular cancer · 2022Article
- PI3K Isoforms in B Cells.Current topics in microbiology and immunology · 2022Article
- Phosphoinositide 3-Kinase p110 Delta Differentially Restrains and Directs Naïve Versus Effector CD8Frontiers in immunology · 2021Article
- PI3Kδ Forms Distinct Multiprotein Complexes at the TCR Signalosome in Naïve and Differentiated CD4Frontiers in immunology · 2021Article
- ConcomitantThe Journal of experimental medicine · 2019Article
- Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment.Immunological reviews · 2019Review
- For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors.Biomolecules · 2019Review
- Macrophage Phosphoproteome Analysis Reveals MINCLE-dependent and -independent Mycobacterial Cord Factor Signaling.Molecular & cellular proteomics : MCP · 2019Article
- Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia.Haematologica · 2018Article
- Signaling and Function of Interleukin-2 in T Lymphocytes.Annual review of immunology · 2018Review
- γδTCR recruits the Syk/PI3K axis to drive proinflammatory differentiation program.The Journal of clinical investigation · 2018Article
- Autosomal Recessive Agammaglobulinemia Due to a Homozygous Mutation in PIK3R1.Journal of clinical immunology · 2018Article
- Class-Switch Recombination (CSR)/Hyper-IgM (HIGM) Syndromes and Phosphoinositide 3-Kinase (PI3K) Defects.Frontiers in immunology · 2018Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The activation of antigen receptors triggers two important signalling pathways originating from phosphatidylinositol(4,5)-bisphosphate [PtdIns(4,5)P(2)]. The first is phospholipase Cgamma (PLCgamma)-mediated hydrolysis of PtdIns(4,5)P(2), resulting in the activation of Ras, protein kinase C and Ca(2+) flux. This culminates in profound alterations in gene expression and effector-cell responses, including secretory granule exocytosis and cytokine production. By contrast, phosphoinositide 3-kinases (PI3Ks) phosphorylate PtdIns(4,5)P(2) to yield phosphatidylinositol(3,4,5)-trisphosphate, activating signalling pathways that overlap with PLCgamma or are PI3K-specific. Pathways that are PI3K-specific include Akt-mediated inactivation of Foxo transcription factors and transcription-independent regulation of glucose uptake and metabolism. The p110delta isoform of PI3K is the main source of PI3K activity following antigen recognition by B cells, T cells and mast cells. Here, we review the roles of p110delta in regulating antigen-dependent responses in these cell types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.